Miraca Life Sciences Announces Significant Tradeshow Plans for the Annual Meeting of the American Academy of Dermatology

Visitors to the Miraca booth will learn about upcoming ICD10 compliance and new CMS requirements for Meaningful Use Stage 2.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Irving, TX (PRWEB) January 14, 2014

Today, Miraca Life Sciences, the nation’s largest independent anatomical pathology provider, announced that it will have a significant presence at the 72nd Annual Meeting of the American Academy of Dermatology, March 21-25th in Denver, CO.

Visitors to Miraca Life Science’s (MLS) booth, #922, can gain important guidance about forthcoming regulatory compliance criteria for Meaningful Use Stage Two. MLS technical directors will be available to help AAD attendees avoid potential Medicare penalties in 2014 and successfully attest to Meaningful Use requirements for Stage Two. MLS technical directors can also help attendees prepare for Meaningful Use audits by ensuring adherence to CMS requirements and explaining the changes and new additions in the second stage of Meaningful Use compliance.

In addition, visitors to Booth #922 will be able to learn how to transition to the next generation of coding systems, ICD-10, that all covered entities will have to adopt by October, 2014. The new ICD-10 coding requirement, which applies to all healthcare providers, will require new processes, new workflows and coordination with payers and clearinghouses. Because ICD-10 impacts the entire practice, not only billing, Miraca Life Sciences is offering important guidance to help practices transition to this new requirement by the deadline.

“We believe every patient deserves the right answer. So when you partner with Miraca, you and your patients benefit from the expertise and support of our entire team of pathology experts,” said Frank Basile, President & CEO of Miraca Life Sciences. “We also employ a team of IT professionals to analyze your particular needs, and then offer solutions tailored to your unique workflow– all to help improve the health of your practice.”

“We have worked with numerous EHR systems and have a strong history of providing workflow efficiencies and solutions to our clients,” noted Gary Rainforth, Vice President of Dermatology Sales for Miraca Life Sciences. “By combining our extensive experience and expertise, we have created a consultative offering that assists healthcare professionals in advancing workflow efficiency and guides them towards full EHR integration. Visitors to MLS’ booth can learn more about our technology partnerships, and receive guidance in choosing, or upgrading, the best EMR system for their practice.”

###

About Miraca Life Sciences
Serving more than 5,500 patients each day, Miraca Life Sciences is a leader in providing an academic-caliber pathology laboratory with diagnostic services in the fields of dermatology, gastroenterology, hematology and urology. Building upon our experience with health IT, we also offer accessible technology solutions to assist healthcare professionals as they work towards accordance with Meaningful Use initiatives.

Miraca Life Sciences, a wholly-owned subsidiary of Japan-based Miraca Holdings Inc., employs a talented team of leading pathologists, histologists, lab technicians, technology consultants, and other medical professionals — all driven to help provide the highest and most up-to-date levels of diagnostic quality, enhanced workflow and practice solutions possible. It is part of our commitment: not only to scientific excellence, but to patients and practices.

About AAD
The American Academy of Dermatology was founded in 1938. It is the largest, most influential and most representative dermatology group in the United States. With a membership of more than 17,000, it represents virtually all practicing dermatologists in the United States, as well as a growing number of international dermatologists.


Contact